IPCA Laboratories: Strong Performance Despite GPM Pressure
Maintain BUY due to good traction in domestic formulations and sustainable growth amid some margin pressure in medium term Target Price and...
226 Views
Ipca Laboratories (IPCA IN): Domestic Business Is the Key Growth Driver
Ipca Laboratories is a fully-integrated generic pharmaceutical company. The company is outpacing the broader market due to its focus on fast moving...
218 Views
Global Equity Strategy U.S. Fed Cut, Now What?
With further consolidation likely for the broad indexes, we want to stick with areas of the market that have shown an ability to outperform despite...
559 Views
IPCA Laboratories- 2QFY19 Results – Growing While Awaiting USFDA Approvals
Ipca Laboratories (IPCA IN) 2QFY19 PAT of Rs 1,197 mn beat our estimates of Rs 1,023 mn. EBITDA margins, excluding forex loss, stood at 20.4%,...
538 Views
IPCA Labs: 1QFY19 Result - International Sales Decline but EBITDA Margins Improve
Ipca Laboratories (IPCA IN) reported revenue growth of 20% YoY at Rs. 8,427 mn, EBITDA at Rs. 1,140 mn and PAT at Rs. 655 mn in 1QFY19 led by low...
371 Views